Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Investing Activities (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cash from Investing Activities for 4 consecutive years, with -$38.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities fell 7027.11% to -$38.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$13.0 million, a 125.97% decrease, with the full-year FY2024 number at $13.1 million, up 22.48% from a year prior.
  • Cash from Investing Activities was -$38.6 million for Q3 2025 at Orchestra BioMed Holdings, down from $16.4 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $33.2 million in Q4 2023 to a low of -$63.4 million in Q4 2022.
  • A 4-year average of -$3.3 million and a median of $557000.0 in 2024 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 5879.91% in 2023; the steepest drop was 92514.89% in 2023.
  • Orchestra BioMed Holdings' Cash from Investing Activities stood at -$63.4 million in 2022, then surged by 152.31% to $33.2 million in 2023, then tumbled by 111.32% to -$3.8 million in 2024, then plummeted by 928.08% to -$38.6 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Cash from Investing Activities are -$38.6 million (Q3 2025), $16.4 million (Q2 2025), and $13.0 million (Q1 2025).